The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Dorsey Brian since 2018.
This trader's CIK number is 1380762.
At the time of last reporting, Dorsey Brian was the Chief Operating Officer of Ars Pharmaceuticals, Inc.. (stock ticker symbol SPRY).
Also see all insider trading activities at Ars Pharmaceuticals, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | SPRY | 0 | $0 | 21,828 | $190,056 | 21,828 | $13,969 |
| 2024 | SPRY | 0 | $0 | 120,000 | $1,633,845 | 120,000 | $76,800 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2018 | APRI | 0 | $0 | 0 | $0 | 81,775 | $0 |
1. Ars Pharmaceuticals, Inc. (SPRY)
2. Seelos Therapeutics, Inc. (APRI)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-11-13 | SPRY | Sale | 21,828 | 8.71 | 190,056 |
| 2025-11-13 | SPRY | Option Ex | 21,828 | .64 | 13,969 |
| 2024-12-11 | SPRY | Option Ex | 15,000 | .64 | 9,600 |
| 2024-12-12 | SPRY | Option Ex | 25,000 | .64 | 16,000 |
| 2024-12-11 | SPRY | Sale | 15,000 | 12.43 | 186,420 |
| 2024-12-12 | SPRY | Sale | 25,000 | 12.30 | 307,425 |
| 2024-08-20 | SPRY | Option Ex | 50,000 | .64 | 32,000 |
| 2024-08-20 | SPRY | Sale | 50,000 | 15.00 | 750,000 |
| 2024-08-13 | SPRY | Option Ex | 30,000 | .64 | 19,200 |
| 2024-08-13 | SPRY | Sale | 30,000 | 13.00 | 390,000 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2018-08-30 | APRI | Option Ex | 81,775 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Dorsey Brian (Chief Operating Officer of Ars Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.